Related references
Note: Only part of the references are listed.Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga et al.
GYNECOLOGIC ONCOLOGY (2019)
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
David W. Doo et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group
Cheryl A. Brewer et al.
GYNECOLOGIC ONCOLOGY (2006)
Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients
RA Nagourney et al.
GYNECOLOGIC ONCOLOGY (2003)